Elevance Health (NYSE:ELV) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Elevance Health (NYSE:ELV) had its price target increased by investment analysts at The Goldman Sachs Group from $350.00 to $370.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective suggests a potential upside of 7.36% from the stock’s current price.

Several other research analysts have also issued reports on the company. Evercore increased their target price on Elevance Health from $345.00 to $360.00 in a research report on Thursday. Wolfe Research set a $425.00 target price on Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Guggenheim increased their target price on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research report on Friday. Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research report on Tuesday, February 3rd. Finally, Wells Fargo & Company decreased their target price on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Eleven investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $380.42.

Elevance Health Stock Down 0.5%

Shares of NYSE:ELV opened at $344.64 on Friday. Elevance Health has a 52-week low of $273.71 and a 52-week high of $427.54. The firm has a market capitalization of $74.84 billion, a P/E ratio of 14.66, a P/E/G ratio of 1.84 and a beta of 0.49. The stock has a 50 day moving average price of $308.96 and a 200-day moving average price of $331.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.48.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the prior year, the company earned $11.97 EPS. The business’s revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities research analysts anticipate that Elevance Health will post 26.79 EPS for the current fiscal year.

Institutional Trading of Elevance Health

Several hedge funds and other institutional investors have recently made changes to their positions in ELV. Norges Bank purchased a new stake in shares of Elevance Health in the 4th quarter worth approximately $1,058,165,000. Wellington Management Group LLP grew its stake in shares of Elevance Health by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after buying an additional 1,668,679 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Elevance Health by 27.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock worth $2,610,261,000 after buying an additional 1,607,274 shares during the last quarter. Invesco Ltd. grew its stake in shares of Elevance Health by 50.3% in the 4th quarter. Invesco Ltd. now owns 3,903,878 shares of the company’s stock worth $1,368,505,000 after buying an additional 1,306,390 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Elevance Health by 79.3% in the 4th quarter. Bank of New York Mellon Corp now owns 2,408,704 shares of the company’s stock worth $844,371,000 after buying an additional 1,065,065 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an “outperform” rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird’s update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.